This table lists all the major pharma collaborations, acquisitions and mergers agreed during October 2014.
For an indepth analysis of these deals, read ‘Pharma deals during October 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Becton Dickinson/CareFusion | Company acquisition | Medical equipment builds US sales base | 12,200 |
| Auxilium/Endo | Company acquisition | Urology and orthopaedic products including alprostadil for ED | 2,600 |
| NewLink Genetics/Genentech | Collaboration and licence | For development of NLG919 and next generation IDO pathway inhibitors | 1,150 |
| Sutro Biopharma/Celgene | Licence plus option to acquire Sutro | For development of multispecific antibodies and antibody drug conjugates (ADCs) | 1,000 |
| Aduro BioTech/J&J | Expansion of collaboration | Lung cancer immunotherapies including ADU 214 | 847 |
| Lineage Therapeutics/Impax Laboratories | Company acquisition | Includes generic and branded products such albendazole and epinephrine | 700 |
| Actavis/Durata Therapeutics | Merger with Actavis subsidiary | Brings Dalvance a recently approved novel antibiotic for acute skin structure infections | 675 |
| Acorda Therapeutics/Civitas Therapeutics | Company acquisition | Includes CVT 301 in P3 for Parkinson’s as well as pulmonary delivery technology | 525 |
| F-star Alpha/BMS | Option to acquire F-star Alpha | Includes FS102 a P1 ready treatment for HER2 positive patients with breast / gastric cancer | 475 |
| CureTech/Medivation | Exclusive global licence | For pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody | 335 |
| Forendo Pharma/Apricus Biosciences | Licence [A] | Fispemifene a selective oestrogen modulator in P2 for secondary hypogonadism | 318 |
| Novartis/CSL | Asset purchase | Influenza vaccines | 275 |
| Five Prime/GSK | Expansion of collaboration | Identifying new agents in asthma and COPD | 196 |
| Bavarian Nordic/J&J | Licence and supply | For multivalent MVA-BN Filovirus vaccine | 187 |
| Lexicon Pharmaceuticals/Ipsen | Licence [B] | Telotristat etiprate in P3 for carcinoid syndrome | 145 |
| Brabant Pharma/Zogenix | Acquisition | Includes fenfluramine for orphan I indication of Dravet syndrome | 130 |
| TesoRx Pharma/Aspen | Licence [C] | For TSX 002 an unmodified oral testosterone replacement | 95 |
| Oxford BioMedica/Novartis | Expansion of collaboration | Lentiviral vectors expressing CTL019 CAR-T therapy for leukaemia | 90 |
| Heidelberg Pharma/Roche | Licence with options to targets | Development of ADCs based on coupling α-amantin to antibodies | 66 |
All deals are worldwide unless otherwise noted.
A: US only
B: Outside N America and Japan
C: Excluding US EU Japan, China and the Middle East